| 商品名 | 申请号 | 产品号 | 申请类型 | 活性成分 | 剂型/给药途径 | 规格/剂量 | RLD | RS | 申请号原始批准/暂定批准日期 | 产品号批准日期 | 申请人 | 市场状态 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RINVOQ | 211675 | 001 | NDA | UPADACITINIB | TABLET, EXTENDED RELEASE;ORAL | 15MG | Yes | No | 2019/08/16 | 2019/08/16 | ABBVIE | Prescription |
| RINVOQ | 211675 | 002 | NDA | UPADACITINIB | TABLET, EXTENDED RELEASE;ORAL | 30MG | Yes | No | 2019/08/16 | 2022/01/14 | ABBVIE | Prescription |
| RINVOQ | 211675 | 003 | NDA | UPADACITINIB | TABLET, EXTENDED RELEASE;ORAL | 45MG | Yes | Yes | 2019/08/16 | 2022/03/16 | ABBVIE | Prescription |
| RINVOQ LQ | 218347 | 001 | NDA | UPADACITINIB | SOLUTION;ORAL | 1MG/ML | Yes | Yes | 2024/04/26 | 2024/04/26 | ABBVIE | Prescription |